BioCentury | Jun 4, 2020
Product Development
June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more
...export pump (BSEP) deficiency who had responded to maralixibat treatment in the open-label Phase II INDIGO...